Benedini Luciano A, Messina Paula V
INQUISUR-CONICET, Department of Chemistry, Universidad Nacional Del Sur, Bahía Blanca B8000CPB, Argentina.
Department of Biology, Biochemistry and Pharmacy, Universidad Nacional Del Sur, Bahía Blanca B8000CPB, Argentina.
Pharmaceutics. 2025 Dec 9;17(12):1588. doi: 10.3390/pharmaceutics17121588.
Smart vesicle therapeutics represent a transformative frontier in nanomedicine, offering precise, biocompatible, and adaptable platforms for drug delivery and theranostic applications. This review explores recent advances in the design and engineering of liposomes, niosomes, polymersomes, and extracellular vesicles (EVs), emphasizing their capacity to integrate therapeutic and diagnostic functions within a single nanoscale system. By tailoring vesicle size, composition, and surface chemistry, researchers have achieved improved pharmacokinetics, reduced immunogenicity, and fine-tuned control of drug release. Stimuli-responsive vesicles activated by pH, temperature, and redox gradients, or external fields enable spatiotemporal regulation of therapeutic action, while hybrid bio-inspired systems merge synthetic stability with natural targeting and biocompatibility. Theranostic vesicles further enhance precision medicine by allowing real-time imaging, monitoring, and adaptive control of treatment efficacy. Despite these advances, challenges in large-scale production, reproducibility, and regulatory standardization still limit clinical translation. Emerging solutions-such as microfluidic manufacturing, artificial intelligence-guided optimization, and multimodal imaging integration-are accelerating the development of personalized, high-performance vesicular therapeutics. Altogether, smart vesicle platforms exemplify the convergence of nanotechnology, biotechnology, and clinical science, driving the next generation of precision therapies that are safer, more effective, and tailored to individual patient needs.